Tag

Takeda Archives - Carey Danis & Lowe

Las Vegas Actos Bladder Cancer Lawsuit Update

By | Actos, Pharmaceutical litigation, Uncategorized

actos_bladder_cancer_lawsuits_settlements_diabetes_litigation_fda_warningClosing arguments concluded before Memorial Day weekend in an Actos bladder cancer lawsuit in a Nevada state court in Las Vegas. The plaintiffs in the case filed their lawsuit targeted at Actos manufacturer, Takeda, claiming that the diabetes drug caused them to develop bladder cancer.

The lawyer representing the plaintiffs, who are two women in their 80s, argued during closing statements that Takeda failed to warn health care providers and patients about the increased risk of bladder cancer when using Actos. Takeda lawyers countered in their closing argument by asserting that Takeda supplied all safety information that was known to them at that time.

The jury in the Las Vegas Actos lawsuit will soon decide whether the plaintiffs should be awarded a compensatory award, and if Takeda is to pay punitive damages. The Las Vegas Actos lawsuit comes on the heels of a $9 billion jury verdict in an Actos lawsuit heard in Louisiana.

The Actos Lawyers at Carey Danis & Lowe

A law firm headquartered in St. Louis, Carey Danis & Lowe specializes in defective pharmaceutical products liability litigation and personal injury lawsuits. If you took Actos, and have developed bladder cancer, you may be eligible to receive compensation for your injuries.

An experienced lawyer at Carey Danis & Lowe is available now to discuss your Actos case during a free case evaluation.

Share your Actos story with us today. Contact Carey Danis & Lowe by phone at 800.721.2519, or by completing a personal injury claim form.

Carey Danis & Lowe Actos Lawyers Comment on Annulled Cooper v. Takeda Compensatory Award

By | Actos, Pharmaceutical litigation, Uncategorized

takeda_pharmaceuticals_actos_bladder_cancer_new_diabetes_drug_combination_alogliptinCarey Danis & Lowe Actos lawyers were optimistic last week when plaintiff Jack Cooper received a compensatory award in the amount of $6.5 million. However, it appears that California Superior Court Judge Kenneth Freeman has annulled Cooper’s award, according to Bloomberg.

Judge Freeman made his ruling to void the $6.5 million compensatory award in Cooper v. Takeda following an argument from Takeda claiming lack of evidence connecting Actos and bladder cancer in the plaintiff.

The plaintiff and his lawyers are seeking an appeal of Judge Freeman’s ruling.

Cooper’s Actos lawsuit was the first to go to trial of approximately 3,000 cases. Individuals who have been injured by Actos have filed their Actos lawsuits alleging that Takeda failed to warn regulators and healthcare providers about the bladder cancer risks associated with use of the diabetes medication.

Despite the nullification of Cooper’s compensatory award, Carey Danis & Lowe Actos lawyers are still confident that the Japanese pharmaceutical company is guilty of wrongdoing. Carey Danis & Lowe encourages individuals who have been injured by Actos use to still seek legal counsel.

Our Actos lawyers are offering free legal evaluations, and can assist in filing an Actos lawsuit. Contact a Carey Danis & Lowe Actos lawyer today by calling 800.721.2519 or by submitting a legal claim form.

Cooper v. Takeda Jury Presented with Plaintiff Closing Argument Linking Actos and Bladder Cancer

By | Actos, Pharmaceutical litigation, Uncategorized

takeda_actos_bladder_cancer_lawsuit_litigation_settlements_trial_filing_risk_cancerTakeda Pharmaceuticals, the Japanese pharmaceutical giant responsible for the development and marketing of the diabetes drug Actos, concealed the association between Actos and bladder cancer, a jury was recently told in an Actos trial.

ccording to a Bloomberg Businessweek report on the Actos trial being heard in Los Angeles, as early as 2004, Takeda knew about the associated between Actos and bladder cancer. Furthermore, with this awareness, the Japanese pharmaceutical company failed to inform the U.S. Food and Drug Administration (FDA), according to the plaintiffs lawyer in the case, Michael Miller.

Closing arguments in the Actos lawsuit were delivered from Miller on April 15, with the jury moving into deliberation on or after April 16 following closing statements from Takeda’s lawyers.

Due to Cooper’s ailing state, Takeda’s lawyers have pointed again and again to Cooper’s health being to blame for his bladder cancer, not Actos. It will be interesting to see if this argument holds any weight during jury deliberation.

The case is Cooper v. Takeda, and is being heard in a California Superior Court in Los Angeles by Judge Kenneth Freeman. As the plaintiff, Jack Cooper, is in poor health, his Actos lawsuit was given priority in going to trial. Once Cooper’s case is settled, Takeda still faces approximately 3,000 more Actos lawsuits, according to a Bloomberg Businessweek report.

The FDA approved Actos in 1999, and since then has ordered Takeda to continually update the drug’s label in order to provide adequate warnings about various health risks associated with Actos use. The current Actos drug label lists a warning about bladder cancer noting that in patients who have used Actos for longer periods, the risk of bladder cancer has increased considerably.

Carey Danis & Lowe Actos lawyers believe that the Cooper Actos case will be representative of and influence future Actos trials and lawsuits. With the evidence brought before the jury in the Cooper case about the dangers of taking Actos, our Actos lawyers believe that injured parties deserve justice and compensation, especially in cases where patients take a drug believing there to be minimal risks, but in reality, these risks have been concealed, resulting in serious harm and injury.

If you or a loved one has been injured by Actos, contact a Carey Danis & Lowe Actos lawyer by calling 800.721.2519 or by submitting a legal claim form.

Carey Danis & Lowe Actos Cancer Lawyers Optimistic Following Cooper v. Takeda $6.5 Million Compensatory Award

By | Actos, Pharmaceutical litigation, Uncategorized

actos_bladder_cancer_lawsuits_settlements_diabetes_litigation_fda_warningA California jury recently awarded a compensatory package of $6.5 million to a plaintiff in an Actos bladder cancer lawsuit. The case, Cooper v. Takeda, was heard over a two month period in a California Superior Court.

The jury arrived at their decision agreeing with Cooper’s claim that Takeda Pharmaceuticals, the manufacturer of the diabetes drug Actos, did not supply adequate safety information about the association between Actos and bladder cancer.

The plaintiff in the case, Jack Cooper, was presented with a $5 million compensatory award. The jury also bestowed a $1.5 million compensatory award upon Cooper’s spouse. Takeda did not have to pay punitive damages in the Actos case.

Carey Danis & Lowe Actos cancer lawyers believe that the jury’s ruling in Cooper’s Actos case delivers much optimism to individuals who have been injured by Actos, and have subsequently filed lawsuits against Takeda.

With the first case having been settled, Takeda faces more than 3,000 Actos lawsuits, according to a Thomson Reuters report. Cooper v. Takeda Pharmaceuticals America Inc. was heard in a California Superior Court in Los Angeles, case number CGC-12-518535.

Actos cancer lawyers at Carey Danis & Lowe are currently offering free legal evaluations of Actos cases. If you or someone you love has been injured by Actos, contact a Carey Danis & Lowe Actos cancer lawyer today by phone at 800.721.2519 or by submitting a legal claim form.

Urologist Testifies in Cooper v. Takeda Actos Lawsuit about Bladder Cancer in California Superior Court

By | Actos, Pharmaceutical litigation, Uncategorized

Urologist Testifies in Cooper v. Takeda Actos Lawsuit about Bladder Cancer in California Superior CourtTestimony provided in late March by a urologist in an Actos trial taking place in a Los Angeles court presented an expert’s opinion about the link between Actos and bladder cancer. A urologist, Dr. Norm D. Smith, testified in Cooper v. Takeda Pharmaceuticals America Inc., a case being heard in a California Superior Court.

According to Dr. Smith, after examining all of the plaintiff’s health factors, it appeared to him that the cause of the plaintiff’s bladder cancer had a more significant connection to a prolonged use of Actos.

The plaintiff in the Actos case, Jack Cooper, took the diabetes drug Actos for five years, and discovered in December 2011 that he had bladder cancer. According to Law360, Cooper filed his Actos bladder cancer lawsuit alleging that Takeda, the Japanese pharmaceutical company responsible for the development and marketing of the drug Actos, neglected to inform healthcare providers about the health complications associated with Actos.

The U.S. Food and Drug Administration (FDA) has been reviewing data collected in a collaborative study conducted by Takeda and Kaiser Permanente Northern California. Their data show that patients who ingest high dosages of Actos for a long period of time, usually more than one year, have a significantly increased risk of developing bladder cancer.

Carey Danis & Lowe Actos bladder cancer lawyers are encouraged by Dr. Smith’s testimony, as it supplies the court and the jury with strong evidence from an expert that, despite the plaintiff’s other health problems and lifestyle choices, the primary reason for the development of his bladder cancer lies in the use of Actos for a long period of time.

Carey Danis & Lowe urges individuals who have been injured by Actos to contact one of our Actos bladder cancer lawyers today for a free legal evaluation about your Actos case, and for assistance in filing an Actos bladder cancer lawsuit.

Contact Carey Danis & Lowe by calling 800.721.2519 or by submitting a legal claim form.

Actos Bladder Cancer Lawsuit News: Pharmacologist Points to Takeda’s Fixation on Profits Over Consumer Safety

By | Actos, Pharmaceutical litigation, Uncategorized

Actos Bladder Cancer Lawsuit News: Pharmacologist Points to Takeda's Fixation on Profits Over Consumer SafetyThe first trial in more than 3,000 Actos lawsuits filed in the U.S. is currently being heard in a Los Angeles court. Lawyers at Carey Danis & Lowe reported last week that the first Actos trial began with revelatory information about Takeda Pharmaceutical’s misleading marketing strategy.

Apparently, the Japanese pharmaceutical company was knowledgeable of the health problems associated with Actos ingestion, but decided to hide that information in order to market the diabetes drug.

Since Carey Danis & Lowe’s update last week, the trial involving plaintiff, Jack Cooper, has convened again for opening arguments from both sides, and expert testimony from a pharmacologist.

Jack Cooper filed a lawsuit against the manufacturer of Actos, Takeda Pharmaceuticals, citing that the pharmaceutical company failed to warn Actos users and healthcare providers about the risks of using the diabetes medicine, especially about the link between Actos and bladder cancer.

A Bloomberg article about the trial states that Cooper developed bladder cancer in 2011. Though Cooper alleges his bladder cancer is a result of ingesting Actos for four years, a lawyer representing Takeda pointed to the plaintiff’s lifestyle to explain his current health condition.

On March 4, Howard Greenberg, a clinical pharamacologist, delivered expert testimony about Takeda’s priorities regarding Actos. Greenberg noted that upon analyzing internal Takeda emails, it became clear that profits from Actos took precedence over consumer safety.

The content of these emails reveals that Takeda executives were concerned about the drug’s viability on the market if pharmaceutical regulators, like the U.S. Food and Drug Administration, ordered that the Actos drug label include information about bladder cancer. These emails go on to express that a bladder cancer warning would be a “worst-case scenario”, according to Bloomberg.

Cooper’s case is being heard in a California Superior Court in Los Angeles, and has been filed as Cooper v. Takeda Pharmaceuticals America Inc.

The worst-case scenario being poor drug sales resulting from a bladder cancer warning illustrates Takeda’s egregious disregard for consumer safety. Lawyers at Carey Danis & Lowe work diligently for our clients to hold pharmaceutical companies accountable for the harm their products cause consumers.

If you or someone you love has been injured by the use of Actos, and as a result, has developed bladder cancer, you and your loved one may be eligible to receive compensation.

For a free legal evaluation and for more information about filing an Actos bladder cancer lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe today by calling 800.721.2519 or by submitting a legal claim form.

First Actos Trial in California Uncovers Takeda’s Deceptive Actos Marketing Tactics

By | Actos, Pharmaceutical litigation, Uncategorized

First Actos Trial in California Uncovers Takeda's Deceptive Actos Marketing TacticsIn 2003, Takeda Pharmaceuticals Inc. expressed concerns about whether Actos users could develop cancer. These reservations on the part of the Japanese pharmaceutical company came to light in court documents filed in a California Superior Court in Los Angeles.

The internal documents reveal that Takeda Pharmaceuticals went so far as to survey doctors about whether a diabetes drug with a label warning about the risk of developing bladder cancer would prevent them from writing a prescription for the drug. After reviewing responses, Takeda Pharmaceuticals concluded that a bladder cancer warning on the Actos label would have a debilitating impact on Actos sales.

Undertaking such a measure is a clear illustration of Takeda Pharmaceuticals’ market-driven philosophy wherein profits far surpass consumer safety in matters of importance.

These internal Takeda documents were filed in the first Actos lawsuit to go to trial. The case is Cooper v. Takeda Pharmaceuticals America, Inc. According to a Bloomberg News report on the Actos trial, there are currently 3,000 Actos lawsuits pending across the country.

These Actos lawsuits including Takeda losing its Actos patent last year are certain to factor in to the company’s reliance on the diabetes drug to be a big moneymaker in 2013. In March 2011, Bloomberg recorded that Actos comprised 27 percent of Takeda’s revenue. Though, this high revenue trend will likely change as Actos has developed a tarnished reputation due to its link to bladder cancer.

In another revealing court filing, Takeda relayed special instructions to its U.S. sales representatives. Essentially, the internal document stated that if safety concerns are not raised, then do not reveal anything about the risk of bladder cancer, and instead, focus on selling the drug.

In response to these documents, a Takeda representative has stated that these documents have been taken out of context.

Lawyers at Carey Danis & Lowe have been paying close attention to the court proceedings in this first Actos lawsuit to go to trial. For those who have been injured by Actos, and especially Actos users who have developed Actos bladder cancer, Carey Danis & Lowe is currently accepting Actos claims, and offering free legal evaluations.

For more information about filing an Actos lawsuit, contact an experienced defective drug lawyer at Carey Danis & Lowe today by calling 800.721.2519 or by submitting a legal claim form

First Actos Trial is Cooper v. Takeda Pharmaceuticals America Inc.

By | Actos, Pharmaceutical litigation, Uncategorized

First Actos Trial is Cooper v. Takeda Pharmaceuticals America Inc.The first Actos lawsuit has gone to trial in a California Superior Court in Los Angeles, known as Cooper v. Takeda Pharmaceuticals America Inc. Cooper v. Takeda is being heard by Judge Kenneth Freeman in California. The plaintiff in the case claims that Takeda failed to warn that one of the risks connected to the diabetes drug is bladder cancer.

To date, there are over 3,000 Actos bladder cancer lawsuits that have been filed against Takeda across the United States in states like California, Illinois, and Louisiana.

In Louisiana, approximately 1,200 Actos lawsuits have been consolidated into a multi-district litigation (MDL). Actos MDL court documents show that the first Actos MDL trial is scheduled for November 2014.

In a report from Bloomberg News, a Takeda representative has publicly stated that the pharmaceutical company has acted appropriately in its response to reports of patients developing bladder cancer linked to Actos ingestion.

However, a U.S. Food and Drug Administration (FDA) analyses of a ten year study conducted by Takeda Pharmaceuticals and Kaiser Permanente Northern California illustrates “increased risk of bladder cancer among patients with the longest exposure to Actos”. Furthermore, the FDA also cited an increased risk of developing bladder cancer in those individuals who ingest high doses of Actos.

Lawyers at Carey Danis & Lowe encourage individuals who have been injured by Actos to contact the law firm for a free legal evaluation and to file an Actos lawsuit. Carey Danis & Lowe believes that it is important to protect consumers and hold negligent pharmaceutical companies, like Takeda, responsible for releasing a harmful drug onto the market.

Contact an experienced trial lawyer at Carey Danis & Lowe by calling 800.721.2519 or by filling out the Carey Danis & Lowe legal claims form.

Takeda Pharmaceuticals Releases New Diabetes Drug with Bladder Cancer Causing Pioglitazone

By | Actos, Pharmaceutical litigation, Uncategorized

takeda_pharmaceuticals_actos_bladder_cancer_new_diabetes_drug_combination_alogliptinThe manufacturer of the diabetes drug Actos, a drug that is tied up in mounting complaints and lawsuits citing the development of bladder cancer, has received U.S. Food and Drug Administration (FDA) approval for a new diabetes drug known generically as alogliptin. The FDA approved three new alogliptin combination drugs for the treatment of type 2 diabetes along with an adjusted diet and exercise regimen.

Takeda has announced that it will release the three drug combinations onto the market beginning in the summer of 2013.

Takeda Pharmaceuticals, a Japanese pharmaceutical company, lost their patent over Actos, known generically as pioglitazone, back in August 2012. With more competition entering into the diabetes drug market, especially with generic versions of Actos, Takeda Pharmaceuticals has introduced three combinations of alogliptin, one of which includes pioglitazone, which is present in Actos.

The alogliptin and pioglitazone drug combination is known as Oseni.

A major concern with the release of Oseni is that, though it will be marketed as a separate drug from Actos, it still contains the same active ingredient present in Actos, known as pioglitazone, a notorious ingredient that has been linked to the development of bladder cancer.

As of yet, however, the only warning given for Oseni is that of congestive heart failure, which is similar to the safety alert the FDA released in August 2007 about Actos and congestive heart failure.

Though it may not be immediately apparent that Oseni proves to be just as harmful as Actos, it is easy to make such a deduction following the mountain of complaints and lawsuits that have sprouted up across the country pertaining to the development of bladder cancer. In light of this, it is egregious that Takeda Pharmaceuticals would release onto the market yet another drug containing an ingredient suspected of causing bladder cancer.

One possible motivation for Takeda’s lack of sensitivity to the harm caused by Actos and pioglitazone is the pharmaceutical giant’s efforts to increase profits. According to a Wall Street Journal article published in early February, Takeda has taken a huge hit in the marketplace with their profits dropping 14 percent. Furthermore, a Bloomberg News report cites that Takeda is anticipating a significantly lower net income through early 2015.

Lawyers at Carey Danis & Lowe are currently evaluating Actos bladder cancer cases. We are also closely monitoring Actos lawsuits being filed around the country. If you or someone you love has been injured by Actos, you and your loved one may be eligible to receive compensation.

For a free legal evaluation about your Actos case, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519.

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in Louisiana

By | Actos, Pharmaceutical litigation, Uncategorized

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in LouisianaParties involved in the Actos multi-district litigation (MDL) in the U.S. District Court for the Western District of Louisiana met for a Status Conference on January 24, 2013. The MDL is known as in re: Actos (Pioglitazone Products Liability Litigation) MDL No. 11-md-2299, and is being presided over by U.S. District Judge Rebecca F. Doherty.

During the most recent Actos MDL Status Conference, the court reviewed recent Actos filings in federal and state courts as well as any new developments since the Actos MDL’s last Status Conference in December 2012. According to an Actos MDL court document, the parties also discussed the progress of the discovery phase. The next Status Conference is scheduled for February 21, 2013.

Plaintiffs whose cases have been consolidated into the Actos MDL have filed their lawsuits against the manufacturer of Actos claiming that the drug caused serious health complications, including bladder cancer.

In a study conducted by Takeda Pharmaceuticals in collaboration with Kaiser Permanente, data shows an increased risk in the development of bladder cancer in patients who have been using Actos for more than 1 year. At this time, the FDA is reviewing information from the Takeda and Kaiser Permanente ten year study. In Europe, healthcare officials have banned sales of Actos following data released from a French epidemiological study that showed a strong link between the ingestion of Actos and the development of bladder cancer.

In other Actos related news, the manufacturer of Actos has received approval to sell a new diabetes drug in the U.S. According to a Bloomberg News report, the Japanese manufacturer of Actos, Takeda Pharmaceuticals, just received approval from the U.S. Food and Drug Administration (FDA) for a new diabetes medication known generically as alogliptin. Takeda Pharmaceuticals intends to market alogliptin in the U.S. by the brand name of Nesina.

Over a five year period, the FDA rejected the new diabetes medication twice before finally granting it approval this month. Whether this new diabetes drug comes with the risk of developing bladder cancer is still uncertain.

Lawyers at Carey Danis & Lowe are currently evaluating Actos claims. If you or someone you love has taken Actos and has subsequently developed bladder cancer, you may be eligible to receive recompense for your pain, suffering, medical expenses, and lost wages.

For a free legal evaluation about your Actos claim and to learn more about filing an Actos bladder cancer lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519 today.